{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:07:23Z","timestamp":1756462043981,"version":"3.41.2"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":106,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biogen International GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>PERFUSE is a non-interventional study of 1233 adult patients (rheumatology, n\u2009=\u2009496; IBD, n\u2009=\u2009737) receiving routine infliximab (IFX) biosimilar SB2 therapy. The aim of this report was to investigate the 12-month persistence, effectiveness and safety outcomes of routine SB2 treatment in patients with chronic inflammatory rheumatic disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with a diagnosis of RA, PsA or axial spondyloarthritis (axSpA) were assigned to one of three study cohorts according to whether SB2 treatment initiated after September 2017 had been the first IFX treatment (IFX na\u00efve) or followed transition from reference IFX (IFX ref) or another IFX biosimilar (IFX bs). Outcomes to month\u200912 (\u00b12) included persistence (primary outcome), SB2 dose, disease status, immunogenicity and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At month\u200912, persistence on SB2 in IFX-na\u00efve, IFX ref and IFX bs cohorts, respectively, [mean percentage (95% CI)] by indication was as follows: 59% (36.1, 76.2), 75% (57.5, 86.1) and 85% (69.6, 93.0) for RA (n\u2009=\u200998); 64% (34.3, 83.3), 87% (65.6, 95.7) and 83% (60.0, 93.1) for PsA (n\u2009=\u200962); and 56% (44.4, 66.5), 80% (70.8, 86.1) and 80% (72.5, 85.6) for axSpA (n\u2009=\u2009336). Disease activity was comparable at baseline and month\u200912 within the IFX ref and bs subgroups of all cohorts by indication. No immunogenicity concerns or new safety signals were detected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SB2 was safe and effective in IFX-na\u00efve patients and in patients transitioned from prior IFX ref or bs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>clinicaltrials.gov, NCT03662919<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkad031","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T14:35:43Z","timestamp":1681742143000},"source":"Crossref","is-referenced-by-count":4,"title":["Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-4274","authenticated-orcid":false,"given":"Bruno","family":"Fautrel","sequence":"first","affiliation":[{"name":"Rheumatology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne University, AP-HP , Paris, France"},{"name":"Pierre Louis Institute for Epidemiology and Public Health, INSERM UMRS 1136 , Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[{"name":"Paris IBD Center, Groupe Hospitalier Priv\u00e9 Ambroise Par\u00e9\u2014Hartmann , Neuilly-sur-Seine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Dieude","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Paris-Cit\u00e9 University, AP-HP , Paris, France"},{"name":"H\u00f4pital Bichat-Claude Bernard, INSERM UMR1152 , Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[{"name":"Rheumatology Department, H\u00f4pital Lariboisi\u00e8re, AP-HP , Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Paris-Cit\u00e9 University, H\u00f4pital Cochin, AP-HP , Paris, France"},{"name":"Clinical Epidemiology and Biostatistics, INSERM (U1153): PRES Sorbonne Paris-Cit\u00e9 , Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Freudensprung","sequence":"additional","affiliation":[{"name":"Biogen GmbH , Baar, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira","family":"Brigui","sequence":"additional","affiliation":[{"name":"Biogen France SAS , Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Addison","sequence":"additional","affiliation":[{"name":"Biogen IDEC , Maidenhead, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"year":"2018","author":"European Medicines Agency","key":"2023042603534433700_rkad031-B1"},{"key":"2023042603534433700_rkad031-B2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/19420862.2016.1264550","article-title":"Physicochemical and biological characterization of SB2, a biosimilar of Remicade\u00ae (infliximab)","volume":"9","author":"Hong","year":"2017","journal-title":"MAbs"},{"key":"2023042603534433700_rkad031-B3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40259-015-0150-5","article-title":"A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade\u00ae) in healthy subjects","volume":"29","author":"Shin","year":"2015","journal-title":"BioDrugs"},{"key":"2023042603534433700_rkad031-B4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","article-title":"A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Choe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023042603534433700_rkad031-B5","doi-asserted-by":"crossref","first-page":"iv49","DOI":"10.1093\/rheumatology\/kex276","article-title":"Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons","volume":"56","author":"Uhlig","year":"2017","journal-title":"Rheumatology (Oxford)"},{"author":"Flixabi","key":"2023042603534433700_rkad031-B6"},{"key":"2023042603534433700_rkad031-B7","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/ctg.2013.13","article-title":"A primer on effectiveness and efficacy trials","volume":"5","author":"Singal","year":"2014","journal-title":"Clin Transl Gastroenterol"},{"key":"2023042603534433700_rkad031-B8","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023042603534433700_rkad031-B9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5152\/eurjrheum.2020.19199","article-title":"Conversion among the 28-joint count activity indices for rheumatoid arthritis","volume":"7","author":"Leong","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"2023042603534433700_rkad031-B10","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2023042603534433700_rkad031-B11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/FTD.0000000000000565","article-title":"Evaluation of infliximab and anti-infliximab LISA-TRACKER immunoassays for the therapeutic drug monitoring of SB2 infliximab biosimilar","volume":"40","author":"Jentzer","year":"2018","journal-title":"Ther Drug Monit"},{"key":"2023042603534433700_rkad031-B12","first-page":"952","article-title":"The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies","volume":"24","author":"Odinet","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"2023042603534433700_rkad031-B13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","article-title":"Nocebos in rheumatology: emerging concepts and their implications for clinical practice","volume":"14","author":"Kravvariti","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2023042603534433700_rkad031-B14","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023042603534433700_rkad031-B15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023042603534433700_rkad031-B16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.semarthrit.2018.07.005","article-title":"Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)","volume":"48","author":"Scherlinger","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2023042603534433700_rkad031-B17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023042603534433700_rkad031-B18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","article-title":"Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab","volume":"27","author":"Tanaka","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2023042603534433700_rkad031-B19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/rheumatology\/keaa502","article-title":"US rheumatologists' beliefs and knowledge about biosimilars: a survey","volume":"60","author":"Gibofsky","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023042603534433700_rkad031-B20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2017-211741","article-title":"Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023042603534433700_rkad031-B21","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.semarthrit.2020.02.007","article-title":"Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice","volume":"50","author":"Lauret","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2023042603534433700_rkad031-B22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/BOR.0b013e3283470f23","article-title":"How to measure disease activity in axial spondyloarthritis?","volume":"23","author":"Machado","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2023042603534433700_rkad031-B23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.sapharm.2018.05.009","article-title":"The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: results of a budget impact analysis","volume":"15","author":"Aladul","year":"2019","journal-title":"Res Social Adm Pharm"},{"key":"2023042603534433700_rkad031-B24","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s12325-019-00998-3","article-title":"Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review","volume":"36","author":"Liu","year":"2019","journal-title":"Adv Ther"},{"key":"2023042603534433700_rkad031-B25","doi-asserted-by":"crossref","first-page":"E1055","DOI":"10.9778\/cmajo.20210091","article-title":"Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis","volume":"9","author":"Gomes","year":"2021","journal-title":"CMAJ Open"},{"key":"2023042603534433700_rkad031-B26","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.2174\/1381612824666171129193708","article-title":"The economic impact of biosimilars on chronic immune-mediated inflammatory diseases","volume":"23","author":"Pentek","year":"2017","journal-title":"Curr Pharm Des"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkad031\/49991921\/rkad031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/2\/rkad031\/50097910\/rkad031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/2\/rkad031\/50097910\/rkad031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T03:54:07Z","timestamp":1682481247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkad031\/7126468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4,12]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkad031","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]},"article-number":"rkad031"}}